Skip to main content
. Author manuscript; available in PMC: 2018 Oct 30.
Published in final edited form as: Lancet Oncol. 2017 Jul 19;18(9):1182–1191. doi: 10.1016/S1470-2045(17)30422-9

Figure 1: Plots of change from baseline in target lesion size over time in patients with metastatic or recurrent colorectal cancer locally assessed as dMMR/MSI-H.

Figure 1:

(A) Percentage change from baseline in the sum of the tumour burden for target lesions over time per investigator assessment for evaluable patients treated with nivolumab. Triangles indicate complete response or partial response per Response Evaluation Criteria In Solid Tumors v1·1; plus signs indicate the first occurrence of a new lesion; solid circle indicate patient who were off treatment; squares indicate percentage change truncated to 100%. (B) Characteristics of response (top panel) or stable disease (bottom panel) evaluated per investigator assessment per Response Evaluation Criteria In Solid Tumors v1·1. The lines represent length of progression-free survival. Triangles indicate censored observations; solid circle indicate the first response; solid black square indicate the last dose when the patient was off treatment; dagger signs indicate death. dMMR/MSI-H=DNA mismatch repair deficient/microsatellite instability–high.